These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27088206)

  • 41. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus.
    Lesiak A; Narbutt J; Sysa-Jedrzejowska A; Lukamowicz J; McCauliffe DP; Wózniacka A
    Lupus; 2010 May; 19(6):683-8. PubMed ID: 20064914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term course of chloroquine retinopathy after cessation of medication.
    Brinkley JR; Dubois EL; Ryan SJ
    Am J Ophthalmol; 1979 Jul; 88(1):1-11. PubMed ID: 463998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy].
    Karkanová M; Matusková V; Vlková E; Dosková H; Uhmannová R
    Cesk Slov Oftalmol; 2010 Apr; 66(2):62-6. PubMed ID: 20925239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
    Flach AJ
    Trans Am Ophthalmol Soc; 2007; 105():191-4; discussion 195-7. PubMed ID: 18427609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy.
    Nebbioso M; Grenga R; Karavitis P
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):249-58. PubMed ID: 19348599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
    Chacón-Dulcey V; López-Labady J; Villarroel-Dorrego M; Frías J; Tirado W; González N; Pérez Alfonzo R
    Lupus; 2020 Jun; 29(7):761-766. PubMed ID: 32362181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
    Leecharoen S; Wangkaew S; Louthrenoo W
    J Med Assoc Thai; 2007 Jan; 90(1):52-8. PubMed ID: 17621733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment.
    Cabral RTS; Klumb EM; Carneiro S
    J Dermatolog Treat; 2020 May; 31(3):264-269. PubMed ID: 30935255
    [No Abstract]   [Full Text] [Related]  

  • 51. [The therapy of systemic lupus erythematosus].
    Ochsendorf FR; Runne U
    Dtsch Med Wochenschr; 1997 Jul; 122(27):877. PubMed ID: 9280702
    [No Abstract]   [Full Text] [Related]  

  • 52. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
    Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
    Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Complications in chloroquin therapy].
    Siegmeth W
    Acta Med Austriaca; 1975; 2(4):116-21. PubMed ID: 1241500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimalarial treatment of rheumatoid arthritis: 1985 status.
    Rynes RI
    J Rheumatol; 1985 Aug; 12(4):657-9. PubMed ID: 4057186
    [No Abstract]   [Full Text] [Related]  

  • 55. [Multimodal imaging of hydroxychloroquine and chloroquine retinopathy].
    Sellam A; Massamba N; Le Hoang P; Bodaghi B
    J Fr Ophtalmol; 2016 Jan; 39(1):111-3. PubMed ID: 26631575
    [No Abstract]   [Full Text] [Related]  

  • 56. Cardiomyopathy related to antimalarial therapy with illustrative case report.
    Costedoat-Chalumeau N; Hulot JS; Amoura Z; Delcourt A; Maisonobe T; Dorent R; Bonnet N; Sablé R; Lechat P; Wechsler B; Piette JC
    Cardiology; 2007; 107(2):73-80. PubMed ID: 16804295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
    Polanski JF; Tanaka EA; Barros H; Chuchene AG; Miguel PTG; Skare TL
    Laryngoscope; 2021 Mar; 131(3):E957-E960. PubMed ID: 32603516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
    Jin Z; Wang F; Pan W; Liu L; Wu M; Hu H; Ding X; Wei H; Zou Y; Qian X; Wang M; Wu J; Tao J; Tan J; Da Z; Zhang M; Li J; Feng X; Sun L
    Rheumatology (Oxford); 2021 Apr; 60(4):1774-1783. PubMed ID: 33099642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Synthetic antimalarials].
    Fardet L; Revuz J
    Ann Dermatol Venereol; 2005; 132(8-9 Pt 1):665-74. PubMed ID: 16230916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.